Barry H, Mutua G, Kibuuka H, et al. - The Ebola vaccination regimen consisting of Ad26.ZEBOV and MVA-BN-Filo is demonstrated as safe and immunogenic in healthy and HIV-infected adults. The regimen induces immune memory that can rapidly be reactivated.

• The urgent medical need during the 2014 to 2016 outbreak led to the acceleration of the clinical development of the 2-dose vaccine regimen consisting of Ad26.ZEBOV and MVA-BN-Filo.

• As part of this accelerated program, the phase 2 study was performed to determine the safety and immunogenicity of the 2-dose vaccine regimen in healthy and HIV-infected African adults, with 28-, 56-, and 84-day intervals between doses.

• Safety and immunogenicity of a booster vaccination with Ad26.ZEBOV, administered nearly 1 year after the first vaccination, were evaluated in healthy adults in this amended study.

• In this randomized trial, 668 healthy 18- to 70-year-olds and 142 HIV-infected 18- to 50-year-olds were randomized to receive intramuscular Ad26.ZEBOV followed by MVA-BN-Filo at 28-, 56-, or 84-day intervals, or saline.

• Participants showed good tolerability towards the vaccine regimen.

• The regimen induced marked immune responses.

• The highest humoral responses were detected after vaccination with 56-day and 84-day intervals.

• Receipt of Ad26.ZEBOV as booster at 1 year after the first dose was linked with induction of anamnestic responses in all healthy participants.